Tharimmune, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
THAR Nasdaq 2830 www.tharimmune.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Tharimmune, Inc.

Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology - Mar 4th, 2025 12:00 pm
Tharimmune to Present at the Microcap Conference 2025 - Jan 27th, 2025 1:30 pm
Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update - Dec 16th, 2024 1:00 pm
Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs - Dec 6th, 2024 9:15 pm
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025 - Nov 27th, 2024 12:00 pm
Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease - Nov 18th, 2024 1:00 pm
Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics - Nov 13th, 2024 1:00 pm
Tharimmune Announces Upcoming Conference Presentations - Nov 4th, 2024 2:00 pm
Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis - Oct 30th, 2024 12:00 pm
Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting - Oct 28th, 2024 1:00 pm
Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company - Sep 30th, 2024 11:00 am
Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab - Sep 16th, 2024 11:00 am
Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board - Jul 22nd, 2024 12:30 pm
Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor - Jul 17th, 2024 12:30 pm
Tharimmune Launches New Website as Discussions with FDA Continue for Phase 2 Clinical Trial with TH104 - Jul 16th, 2024 12:30 pm
Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis - Jun 10th, 2024 12:00 pm
Tharimmune to Present at 2024 BIO International Convention - May 29th, 2024 12:30 pm
Tharimmune Announces 1-for-15 Reverse Stock Split - May 22nd, 2024 11:00 am
Stonegate Healthcare Partners Updates Report on Transformative Therapies for Pruritus Management - May 2nd, 2024 5:34 pm
Tharimmune To Participate in Two Upcoming Investor Conferences in May - Apr 30th, 2024 12:31 pm